Thursday, October 26, 2017
Evotec and Aptuit announced that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $300 million. This transaction will strengthen Evotec’s position as the leading global player in the external innovation marketplace. As a partner research organization for integrated outsourced drug discovery and development solutions, Aptuit offers highly synergistic scientific expertise across drug discovery, pre-clinical testing and both drug substance and drug product manufacturing to its Biopharma partners. The acquisition will add considerable business opportunities to further accelerate Evotec’s long-term strategy to be the industry partner of choice for external innovation.
Research and Markets has announced the addition of the “Oncology Based In-vivo CRO Market Analysis By Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2014 – 2025” report to their offering.
Evotec has joined the NURTuRE consortium to drive kidney disease focused drug discovery based on patient derived-data. NURTuRE is uniquely positioned to collect clinical data at the U.K. Renal Registry and analyze samples of 14 kidney disease centers in the U.K., constituting one of the largest kidney patient registries worldwide.
Evotec and MaRS Innovation have announced the launch of Fibrocor Therapeutics, a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. The company was launched with CDN $2.8 million (approx. $ 2.1 million) financing, which includes cash from MaRS Innovation. Evotec will provide all drug discovery activities and will also receive an equity stake.
Evotec will extend its existing relationship with Eternygen by becoming an investor in addition to being a preclinical drug discovery partner. Within a consortium of investors including VC Fonds Technologie Berlin, managed by IBB Beteiligungsgesellschaft mbH, and two renowned family offices, Epidarex and Evotec together will participate in Eternygen’s latest funding round of EUR 8 million (approx. $8.3 million).
Evotec and Celgene have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, and multiple other neurodegenerative disorders.
Evotec has announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck’s portfolio of genome editing technologies with Evotec’s versatile screening platforms and disease expertise. Evotec will leverage Merck’s comprehensive collection of genetic reagents such as viral CRISPR and shRNA libraries to enable new target discovery programs using its capabilities for phenotypic screening in primary and induced pluripotent stem (iPS) cells, as well as its in vivo disease models. Bringing together the complementary offerings, the two companies aim to provide fast and validated workflows to clients seeking to explore a new target space within complex disease models.
Evotec has announced a novel strategic partnership with the University of Oxford, the university’s research commercialization company Oxford University Innovation (OUI) and Oxford Sciences Innovation, an IP investment company dedicated to a single university (OSI) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics. Projects will be sourced exclusively from Oxford University researchers via OUI across any therapeutic area and for any therapeutic modality and will be aided by a drug discovery expert in residence seconded by Evotec to the LAB282 initiative and embedded in the university.
Bayer and Evotec have entered into a five-year, multi-target research partnership to develop multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during preclinical development of potential clinical candidates.